Yangyang Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yangyang Song has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Leilei Chen
Cancer Science Institute of Singapore, National University of Singapore
16 shared publications - Omer An
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
14 shared publications - Vanessa Hui En Ng
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
11 shared publications - Fernando Bellido Molias
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh
9 shared publications Andre Sim
6 shared publicationsJasmin Xin Jia Teo
6 shared publications
Latest Publications
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (120) , eaea6909
DDX6 induces immunosuppression in cancer by disrupting structural stability of endogenous double-stranded RNAs
Cellular double-stranded RNA (dsRNA) can activate immune pathways similar to viral RNA. Adenosine deaminases acting on RNA 1 (ADAR1)–mediated adenosine-to-inosine (A-to-I) RNA editing has long been believed to destabilize endogenous dsRNA, thus preventing immune activation. We identified DEAD-box RNA helicase 6 (DDX6) as a potent editing repressor and an immune protector under normal conditions but as an immunosuppressor in cancer contexts. Through its interaction with ADAR1, DDX6 binds preferentially to cytoplasmic dsRNA, repressing editing of adenosines in A:C mismatches across the transcriptome, disrupting dsRNA structural stability, and suppressing interferon signaling and immune responses. Depleting DDX6 in tumor cells triggers dsRNA accumulation and activates both intrinsic and extrinsic immunity to hinder tumor growth. Our findings broaden our understanding of the paradigm that RNA editing not only destabilizes cellular dsRNAs but also can stabilize them through I-C pairing, a process preferentially suppressed by DDX6, to limit cytosolic dsRNA sensor recognition. Targeting DDX6 and harnessing RNA-associated tumor cell–intrinsic innate immune activation holds promise for cancer immunotherapy.
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (120) , eaea6909
DDX6 induces immunosuppression in cancer by disrupting structural stability of endogenous double-stranded RNAs
Cellular double-stranded RNA (dsRNA) can activate immune pathways similar to viral RNA. Adenosine deaminases acting on RNA 1 (ADAR1)–mediated adenosine-to-inosine (A-to-I) RNA editing has long been believed to destabilize endogenous dsRNA, thus preventing immune activation. We identified DEAD-box RNA helicase 6 (DDX6) as a potent editing repressor and an immune protector under normal conditions but as an immunosuppressor in cancer contexts. Through its interaction with ADAR1, DDX6 binds preferentially to cytoplasmic dsRNA, repressing editing of adenosines in A:C mismatches across the transcriptome, disrupting dsRNA structural stability, and suppressing interferon signaling and immune responses. Depleting DDX6 in tumor cells triggers dsRNA accumulation and activates both intrinsic and extrinsic immunity to hinder tumor growth. Our findings broaden our understanding of the paradigm that RNA editing not only destabilizes cellular dsRNAs but also can stabilize them through I-C pairing, a process preferentially suppressed by DDX6, to limit cytosolic dsRNA sensor recognition. Targeting DDX6 and harnessing RNA-associated tumor cell–intrinsic innate immune activation holds promise for cancer immunotherapy.
- 15 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 14 (24) , 10695-10704
First-principles study on magnetic MXenes for free radical trapping and sensing
Driven by first-principles design, magnetic MXenes are identified as highly efficient capture agents for radicals. Their pronounced magnetic and SHC variations pave the way for designing portable, signal-responsive radical scavengers.
- 15 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry C
- Vol. 14 (24) , 10695-10704
First-principles study on magnetic MXenes for free radical trapping and sensing
Driven by first-principles design, magnetic MXenes are identified as highly efficient capture agents for radicals. Their pronounced magnetic and SHC variations pave the way for designing portable, signal-responsive radical scavengers.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer
List of ncNATs expressed in TCGA tumors, for which their associated sense genes have two active alternative promoters
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer
List of ncNATs expressed in TCGA tumors, for which their associated sense genes have two active alternative promoters
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer
List of 353 unique ncNATs expressed in tumors of one or multiple tumor types from TCGA.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer
List of 353 unique ncNATs expressed in tumors of one or multiple tumor types from TCGA.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer
List of 521 unique ncNATs expressed in non-tumor samples of one or multiple cancer/tissue types from TCGA and GTEx.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer
List of 521 unique ncNATs expressed in non-tumor samples of one or multiple cancer/tissue types from TCGA and GTEx.
- 16 February 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (25) , 3078-3090
Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis
Adenosine to inosine (A-to-I) RNA editing, which is catalyzed by adenosine deaminases acting on RNA (ADAR) family of enzymes ADAR1 and ADAR2, has been shown to contribute to multiple cancers. However, other than chronic myeloid leukemia (CML) blast crisis, relatively little is known about its role in other types of hematological malignancies. Here, we found that ADAR2, but not ADAR1 and ADAR3, was specifically downregulated in the core binding factor (CBF) AML with t(8;21) or inv(16) translocations. In t(8;21) AML, RUNX1-driven transcription of ADAR2 was repressed by the RUNX1-ETO AE9a fusion protein in a dominant negative manner. Further functional studies confirmed that ADAR2 could suppress leukemogenesis specifically in t(8;21) and inv16 AML cells dependent on its RNA editing capability. Expression of two exemplary ADAR2-regulated RNA editing targets COPA and COG3 inhibited clonogenic growth of human t(8;21) AML cells. Our findings support a hitherto unappreciated mechanism leading to ADAR2 dysregulation in CBF AML and highlight the functional relevance of loss of ADAR2-mediated RNA editing to CBF AML.
- 16 February 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (25) , 3078-3090
Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis
Adenosine to inosine (A-to-I) RNA editing, which is catalyzed by adenosine deaminases acting on RNA (ADAR) family of enzymes ADAR1 and ADAR2, has been shown to contribute to multiple cancers. However, other than chronic myeloid leukemia (CML) blast crisis, relatively little is known about its role in other types of hematological malignancies. Here, we found that ADAR2, but not ADAR1 and ADAR3, was specifically downregulated in the core binding factor (CBF) AML with t(8;21) or inv(16) translocations. In t(8;21) AML, RUNX1-driven transcription of ADAR2 was repressed by the RUNX1-ETO AE9a fusion protein in a dominant negative manner. Further functional studies confirmed that ADAR2 could suppress leukemogenesis specifically in t(8;21) and inv16 AML cells dependent on its RNA editing capability. Expression of two exemplary ADAR2-regulated RNA editing targets COPA and COG3 inhibited clonogenic growth of human t(8;21) AML cells. Our findings support a hitherto unappreciated mechanism leading to ADAR2 dysregulation in CBF AML and highlight the functional relevance of loss of ADAR2-mediated RNA editing to CBF AML.